Published 9 days ago • loading... • Updated 9 days ago

Kelun-Biotech Announces Approximately US$250 Million Placement

On June 5th, 2025, Kelun-Biotech, a biopharmaceutical company based in Sichuan, issued 5,918,000 H shares on the Hong Kong stock exchange under its general mandate.
The placement followed an upsized target from US$200 million to US$250 million due to strong demand from investors including sovereign wealth and healthcare specialist funds.
The shares priced at HK$331.8 each, representing a 7.58% discount to the last close and a 0.89% premium to the five-day average, were multiple times oversubscribed.
Kelun-Biotech's CEO, Dr. Michael Ge, expressed satisfaction with the ongoing backing from their major current shareholders, as well as the involvement of prominent new investors.
Kelun-Biotech plans to use the approximately US$250 million net proceeds to advance research, clinical trials, and global drug development efforts.

Insights by Ground AI

Does this summary seem wrong?

61 Articles

All

Left

Center

Right

Rutland Herald

+59 Reposted by 59 other sources

Center

Kelun-Biotech Announces Approximately US$250 Million Placement

CHENGDU, China, June 5, 2025 /PRNewswire/ -- On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital…

9 days ago

Read Full Article

endpoints.news

Kelun's $250M PIPE; Valneva moves chikungunya vaccine to Phase 3 for kids

Plus, news about Trevi Therapeutics: Kelun Biotech’s $250M stock sale: The Sichuan company upsized its PIPE from $200 to $250 million and included investors from around the globe, including sovereign wealth funds and healthcare specialist ...

9 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year